Stock traders are buying a high volume of put options on Amyris (NASDAQ:AMRS)
Amyris, Inc. (NASDAQ:AMRS – Get Rating) saw unusual options trading on Monday. Investors bought 13,356 put options on the company. This represents a 67% increase from the typical volume of 8,020 puts.
Amyris share performance
NASDAQ: AMRS traded down $0.23 at midday on Monday, hitting $2.93. 247,686 shares were traded, against an average volume of 6,302,140. The company has a 50-day simple moving average of $2.32 and a 200-day simple moving average of $3.18. The stock has a market capitalization of $941.71 million, a P/E ratio of -1.94 and a beta of 1.62. The company has a quick ratio of 1.13, a current ratio of 1.66 and a debt ratio of 1.26. Amyris has a 1-year low of $1.47 and a 1-year high of $16.31.
Amyris (NASDAQ:AMRS – Get Rating) last released its quarterly results on Tuesday, August 9. The biotech company reported ($0.34) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.28) by ($0.06). The company posted revenue of $65.20 million in the quarter, compared to $81.53 million expected by analysts. The company’s revenue increased by 24.7% compared to the same quarter last year. During the same quarter of the previous year, the company achieved EPS of ($0.16). Analysts expect Amyris to post -1.11 earnings per share for the current fiscal year.
A Wall Street analyst gives his opinion
AMRS has been the subject of several reports by research analysts. Piper Sandler kicked off Amyris coverage in a research report on Wednesday, May 25. They set a “neutral” rating and a target price of $2.50 on the stock. Roth Capital downgraded Amyris from a “buy” rating to a “neutral” rating in a Wednesday, August 10 research report. Finally, JPMorgan Chase & Co. launched coverage on Amyris in a research report on Friday, June 24. They set a “neutral” rating on the stock.
Insider Activity at Amyris
In related news, insider Nicole Kelsey sold 94,033 shares of the company in a trade dated Thursday, June 30. The stock was sold at an average price of $1.80, for a total transaction of $169,259.40. Following the completion of the transaction, the insider now directly owns 63,333 shares of the company, valued at approximately $113,999.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. In other Amyris news, CFO Hermanus Kieftenbeld sold 34,905 shares in a trade dated Thursday, June 2. The stock was sold at an average price of $2.34, for a total value of $81,677.70. Following the sale, the CFO now owns 266,655 shares of the company, valued at approximately $623,972.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, insider Nicole Kelsey sold 94,033 shares in a trade dated Thursday, June 30. The shares were sold at an average price of $1.80, for a total value of $169,259.40. Following the completion of the sale, the insider now directly owns 63,333 shares of the company, valued at approximately $113,999.40. The disclosure of this sale can be found here. Insiders have sold 199,225 shares of the company worth $403,182 over the past three months. 33.80% of the shares are held by insiders of the company.
Institutional entries and exits
A number of hedge funds have recently increased or reduced their holdings in AMRS. Teacher Retirement System of Texas increased its stake in Amyris shares by 10.9% in Q1. Teacher Retirement System of Texas now owns 35,431 shares of the biotech company valued at $154,000 after buying 3,471 additional shares in the last quarter. American International Group Inc. increased its stake in Amyris shares by 5.0% in the second quarter. American International Group Inc. now owns 92,152 shares of the biotech company valued at $170,000 after buying 4,349 additional shares in the last quarter. Sabal Trust CO increased its stake in Amyris shares by 36.0% in the 1st quarter. Sabal Trust CO now owns 17,000 shares of the biotech company valued at $74,000 after buying an additional 4,500 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in Amyris shares in Q4, valued at around $26,000. Finally, Legal & General Group Plc increased its stake in Amyris shares by 3.6% in the second quarter. Legal & General Group Plc now owns 142,454 shares of the biotech company valued at $263,000 after buying an additional 4,956 shares last quarter. Hedge funds and other institutional investors hold 49.43% of the company’s shares.
(Get a rating)
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, flavor and fragrance markets in Europe, North America, Asia and South America. The Company manufactures and sells clean beauty, personal care, health and wellness consumer products and ingredients for the flavor and fragrance, nutrition, food and beverage, beauty end markets. clean and personal care.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Amyris, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Amyris wasn’t on the list.
While Amyris currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here